Le Lézard
Classified in: Health
Subjects: LEG, AVO

Four Medical Associations Aim to Ease Access to Prescription Medication for Opioid Use Disorder

PHOENIX, July 30, 2019 /PRNewswire-PRWeb/ -- The American College of Medical Toxicology recently published a Position Statement that strongly recommends removing the waiver ('X-waiver') requirement for prescribing buprenorphine for opioid use disorder (OUD). ACMT's position has been endorsed by the American Academy of Clinical Toxicology, the American Academy of Emergency Medicine, and the American College of Emergency Physicians.

The Position states, "The ongoing epidemic of opioid overdose deaths represents a major public health crisis, with more than 48,000 Americans estimated to have died from opioid overdose in 2017 alone. Opioid use disorder (OUD) is a chronic medical condition that can be treated with pharmacological therapies. In response to growing evidence, there is consensus within the healthcare community that Opioid Agonist Therapy (OAT) is the best practice for the management of OUD. Therapy with buprenorphine, a form of OAT, reduces the risk of death in patients with OUD, prevents complications from nonfatal opioid overdose, prevents injection-associated infections, improves overall functional status, and is cost-effective".

Currently, US law requires prescribers to obtain a waiver for outpatient prescription of buprenorphine, which is one of three medications approved to treat opioid addiction in the US. Prescribers must complete an approved training and submit an application to the Substance Abuse and Mental Health Services Administration. Once approved, the Drug Enforcement Agency issues a registration number beginning with X (the so-called "x-waiver") for outpatient prescribing of buprenorphine. Today, fewer than 5% of eligible prescribers in the US have a waiver to prescribe buprenorphine.

If the 'X-waiver' regulation is lifted, outpatient access to buprenorphine, a medication that has been demonstrated to be safe, cost-effective, and lifesaving, will positively affect patients with OUD.

Link to Position Statement

ACMT?Advancing the Toxicological Care of Poisoned Patients and Populations
The American College of Medical Toxicology (ACMT) is a professional, nonprofit association of physicians with recognized expertise and board certification in medical toxicology. Our members specialize in the prevention, evaluation, treatment, and monitoring of injury and illness from exposures to drugs and chemicals, as well as biological and radiological agents. ACMT members work in clinical, academic, governmental, and public health settings, and provide poison control center leadership.


SOURCE American College of Medical Toxicology

These press releases may also interest you

at 03:00
The plastic and reconstructive surgeons at The Institute for Advanced Reconstruction (IFAR) at The Plastic Surgery Center in New Jersey epitomize the notion that plastic surgery is much more than just cosmetic surgery and far more extensive than how...

at 03:00
Ervaxxtm, a biotechnology company pioneering the use of Dark Antigenstm to develop T-cell receptor (TCR)-based immunotherapies and off-the-shelf cancer vaccines, has entered a licensing and research collaboration with a leading T-cell immunology...

at 02:05
The Healthcare Information and Management Systems Society (HIMSS) and Elsevier, the global information analytics business specializing in science and health, are proud to announce the call for submissions for the Annual HIMSS-Elsevier Digital...

at 01:05
Regulatory News: Lysogene (Paris:LYS) (FR0013233475 ? LYS) today announced its corporate agenda* for 2020: 17 February 2020: Sales and cash position at the end of 2019 20 March 2020: 2019 annual results 22 April 2020: First...

at 01:05
Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that the Phase III IMvigor010 study evaluating Tecentriq® (atezolizumab) as an adjuvant (after surgery) monotherapy treatment did not meet its primary endpoint of...

at 01:05
Regulatory News: Ipsen (Euronext: IPN; ADR: IPSEY) today announced the decision to pause dosing patients in the global Phase III (PVO-1A-301) study designed to evaluate the efficacy and safety of palovarotene in patients with fibrodysplasia...

News published on 30 july 2019 at 09:40 and distributed by: